# Relations of Epicardial Adipose Tissue Volume, Thyroid Axis Hormones and Microalbuminuria to Coronary Artery Calcium in Type 2 Diabetic Patients

Thesis

Submitted for Partial Fulfillment of M.D. Degree in Endocrinology and Metabolism

BY

#### **Ahmed Mohamed Abd El-Fatah Hamam**

Master of Sciences in Endocrinology and Metabolism - Ain Shams University

#### **Supervised by**

#### Prof. Hussein Abd El-Hai El-Orabi

Professor of Internal Medicine and Endocrinology Faculty of Medicine - Ain Shams University

#### Maj. Gen. (Dr.) Said Abd El-Hafez Mohram

Professor of Cardiology – Military Medical Academy

#### Dr. Khaled Mahmoud Makbol

Assistant Professor of Internal Medicine and Endocrinology Faculty of Medicine - Ain Shams University

#### Dr. Yara Mohamed Eid


Assistant Professor of Internal Medicine and Endocrinology Faculty of Medicine - Ain Shams University

#### Dr. Maram Mohamed Maher

Lecturer of Internal Medicine and Endocrinology Faculty of Medicine - Ain Shams University

Faculty of Medicine
Ain Shams University
2014





#### **ACKNOWLEDGMENTS**

First of all thanks to **ALLAH** who gives us the gift of knowledge and understand.

I am grateful to **Prof. Hussein Abd El-Hai El-Orabi**, Professor of Internal Medicine and Endocrinology, Faculty of Medicine-Ain Shams University, for his wide knowledge, understanding, encouraging and personal guidance have provided me with great information to come up with this work. His valuable guidance and long experience have affected the outcome of this work.

I am deeply thankful to **Maj. Gen. Said Abd El-Hafez**, Professor of cardiology, Military medical Academy, for his kind supervision, and great help throughout this work

I am deeply indebted and grateful to **Dr. Khaled Mahmoud Makbol**, Ass. Professor of Internal Medicine and Endocrinology, Faculty
of Medicine-Ain Shams University, for his supervision, continous help,
valuable encouragement and continous guidance.

I am so much obligated to **Dr. Yara Mohamed Eid**, Ass. Professor of Internal Medicine and Endocrinology, Faculty of Medicine-Ain Shams University, who offered much of her time and advice through my work in this study. Her kind assistance, great support and sincere cooperation have affected the outcome of this work.

I owe my deepest gratitude to **Dr. Maram Mohamed Maher**, lecturer of Internal Medicine and Endocrinology, Faculty of Medicine-Ain Shams University, for valuable guidance, support, advice and for effort in the presentation of this work.

Lastly but not least I would like to extend my warm thanks to all my professors, staff members and colleagues in the Military Hospitals for their continuous help and support.



### **CONTENTS**

|   | Page |
|---|------|
| Acknowledgments   | I    |
| List of abbreviations   | II   |
| List of figures   | VI   |
| List of tables  | VIII |
| Protocol  | X    |
|   |      |
| Review of literature  |      |
| Chapter 1:  |      |
| Adipose tissue  | 1    |
| Chapter 2:  |      |
| Diabetes and cardiovascular disease                             | 32   |
| Chapter 3:  |      |
| <ul><li>Diabetes and thyroid hormones.</li></ul>                | 59   |
| <ul> <li>Thyroid hormones and cardiovascular disease</li> </ul> | 74   |
| Chapter 4:  |      |
| Coronary artery calcium   | 81   |
| Patients and methods  | 96   |
| Results   | 110  |
| Discussion  |      |
| Summary and conclusions   | 155  |
| Recommendations   | 159  |
| References  | 160  |
| Arabic summary  |      |



## **List of Abbreviations**

| 2h PG               | 2 hours plasma glucose during OGTT                    |
|---------------------|---|
| <sup>18</sup> F-FDG | <sup>18</sup> F-fluorodeoxyglucose                    |
| ABPI                | The ankle brachial pressure index                     |
| ACCF/AHA            | American College of Cardiology Foundation/American    |
|                     | Heart Association                                     |
| ACCORD              | Action to Control Cardiovascular Risk in Diabetes     |
| ACS                 | Acute coronary syndrome                               |
| ADA                 | American Diabetic Association                         |
| ADVANCE             | Action in Diabetes and Vascular Disease: Preterax and |
|                     | Diamicron Modified Release Controlled Evaluation      |
| AGES                | Advanced glycation end products                       |
| AITD                | Autoimmune thyroid dysfunction                        |
| Akt2                | Protein kinase B                                      |
| AMPK                | 5` adenosine monophosphate activated protein kinase   |
| ANDROMEDA           | European Trial of Dronedarone in Moderate to Severe   |
|                     | Congestive Heart Failure                              |
| ANGPTL2             | Angiopoietin-like protein 2                           |
| ANS                 | Autonomic Nervous System                              |
| ASA                 | Acetylsalicylic acid                                  |
| AT                  | Adipose tissue  |
| AUC                 | Area under the curve                                  |
| BAT                 | Brown adipose tissue                                  |
| BP                  | Blood pressure  |
| CAC                 | Coronary artery calcium                               |
| CAD                 | Coronary artery disease                               |
| CAN                 | Cardiovascular Autonomic Neuropathy                   |
| CARDS               | Collaborative Atorvastatin Diabetes Study             |
| CCL2                | CC-chemokine ligand 2                                 |
| CCTA                | Coronary CT Angiography                               |
| CHD                 | Coronary heart disease                                |
| ChREBP              | Carbohydrate response element binding protein         |
| C-IMT               | Carotid intima media thickness                        |
| CRP                 | C-reactive protein;                                   |
| СТ                  | Computed tomography                                   |
| CVD                 | Cardiovascular diseases                               |
| CXCL5               | CXC-chemokine ligand 5                                |
| D                   | Deiodinase  |
| ·                   |   |



| DCCT/EDIC    | Diabetes Control and Complications Trial/Epidemiology  |
|--------------|--|
| BeenEBie     | of Diabetes Interventions and Complications            |
| DIAD         | Detection of Silent Myocardial Ischemia in             |
|              | Asymptomatic Diabetic Subjects                         |
| DIO2         | Deiodinase type 2                                      |
| DPP          | The Diabetes Prevention Program                        |
| EAT          | Epicardial adipose tissue                              |
| EBCT         | Electron beam computed tomography                      |
| EISNER       | Early Identification of Subclinical Atherosclerosis by |
| LISINLIK     | Noninvasive Imaging Research                           |
| FFA          | Free fatty acids;                                      |
| FFAs         | Free fatty acids                                       |
| FIELD        | The Fenofibrate Intervention and Event Lowering in     |
|              | Diabetes study   |
| FPG          | Fasting plasma glucose                                 |
| FRS          | Framingham Risk Score                                  |
| Gi           | Inhibitory G protein                                   |
| GLUT         | Glucose transporter                                    |
| HATS         | The HDL Atherosclerosis Treatment Study                |
| HDL          | High density lipoprotein                               |
| HIV          | Human immunodeficiency virus                           |
| ICAM         | Intercellular adhesion molecule                        |
| IFN          | Interferon   |
| IL           | Interleukin  |
| IL-1Ra       | Interleukin-1 receptor antagonist;                     |
| iNOS         | Inducible nitric oxide synthase                        |
| JNK          | c-Jun N-terminal kinase;                               |
| LDL          | Low density lipoprotein cholesterol                    |
| MAU          | Microalbuminuria                                       |
| MCP          | Monocyte chemoattractant protein                       |
| MDCT         | Multi-detector computed tomography                     |
| MESA         | The Multi-Ethnic Study of Atherosclerosis              |
| MI           | Myocardial infarction                                  |
| MMP          | Matrix metalloproitenase;                              |
| MRI          | Magnetic-resonance imaging                             |
| mTOR         | Mammalian target of Rapamycin                          |
| MDCT         | Multidetector computed tomography                      |
| NADPH        | Nicotinamide adenine dinucleotide phosphate            |
| NAMPT        | Nicotinamide phosphoribosyltransferase                 |
| NCEP ATP III | National Cholesterol Education Program Adult           |
|              | Treatment Panel III Guidelines                         |



| NE             | Noroninonhrino   |
|----------------|--|
|                | Norepinephrine Nuclear factor frame 0                    |
| NF-κβ          | Nuclear factor kappa-β                                   |
| NGF            | Nerve growth factor;                                     |
| NHANES         | National Health and Nutrition Examination Survey         |
| n-HDL          | Non- high density lipoprotein                            |
| NOS            | Nitric oxide synthase                                    |
| PAI            | Plasminogen activator inhibitor                          |
| PC             | Pyruvate carboxylase                                     |
| PEPCK          | Phosphoenolpyruvate kinase                               |
| PET            | Positron-emission tomography                             |
| PGC-1 alpha    | PPAR gamma coactivator-1 alpha                           |
| PGK            | Phosphoglycerate kinase                                  |
| PKC            | The activation of protein kinase C                       |
| PPAR           | Peroxisome proliferator-activated receptor               |
| PRDM16         | Brown adipocyte differentiation transcription factor PR- |
|                | domain-missing16   |
| PREDICT        | Patients with Renal Impairment and Diabetes              |
|                | undergoing Computed Tomography,                          |
| PVAT           | Perivascular adipose tissue                              |
| OGTT           | Oral glucose tolerance test                              |
| oxLDL          | oxLDL  |
| RANTES         | Regulated upon activation normal T cell and secreted     |
| RBP4           | Renitol-binding protein 4                                |
| RNS            | Reactive nitrogen species                                |
| ROS            | Reactive oxygen species                                  |
| rT3            | Reverse T3   |
| SBP            | Systolic blood pressure                                  |
| sFRP5          | Frizzled-related protein 5                               |
| SMI            | Silent myocardial ischemia                               |
| sPLA2-IIA      | Secretory type II phospholipase A2                       |
| T1DM           | Type 1 diabetes mellitus                                 |
| T2DM           | Type 2 diabetes mellitus                                 |
| T3             | Triiodothyronine   |
| TGs            | Triglycerides  |
| T <sub>H</sub> | T helper   |
| TH             | Thyroid hormones   |
| TLRs           | Toll-like receptors                                      |
| TNF            | Tumor necrosis factor                                    |
| TR             | Thyroid receptor   |
| TSH            | Thyroid-stimulating hormone                              |
| 1011           | Thyrora-summaning normone                                |



| UACR   | Urinary albumin/ creatinine ratio         |
|--------|---|
| UAE    | urinary albumin excretion                 |
| UCP-1  | Uncoupling protein-1                      |
| UKPDS  | United Kingdom Prospective Diabetes Study |
| VADT   | Veterans Affairs Diabetes Trial           |
| VCAM-1 | Vascular cell adhesion molecule-1;        |
| VEFG   | Vascular endothelial growth factor;       |
| VLDL   | Very low-density lipoprotein cholesterol, |
| VSMC   | Vascular smooth muscle cells              |
| WAT    | White adipose tissue                      |
| WHO    | World Health Organization                 |



## **List of Figures**

|             |  | Page |
|-------------|--|------|
| A: Figures  | s of the Review:   |      |
| Figure (1)  | Schematic illustration of adipose tissue   | 4    |
| Figure (2)  | Schematic illustration of a large and small adipose depot  | 4    |
| Figure (3)  | Adipose tissue depots  | 5    |
| Figure (4)  | Components of adipose tissue   | 7    |
| Figure (5)  | Phenotypic modulation of adipose tissue  | 8    |
| Figure (6)  | Microscopic imaging of human epicardial fat  | 14   |
| Figure (7)  | Potential physiological, pathophysiological mechanisms and vasocrine/ paracrine pathways of epicardial fat                     | 17   |
| Figure (8)  | Schematic diagram outlining the regulatory balance between adiponectin and leptin on mediators of atherogenesis                | 30   |
| Figure (9)  | Pathogenesis of cardiovascular disease in diabetes   | 37   |
| Figure (10) | The relation between hyperthyroidism and hyperglycemia via lipid Metabolism oxidative stress and hepatic dysfunction           | 62   |
| Figure (11) | The relation between hypothyroidism and hypoglycemia mediated by reduced insulin synthesis and impaired hepatic glucose output | 63   |
| Figure (12) | Coronary artery calcium scans showing progressively increasing Agatston score  | 82   |
| B: Figures  | of the Results:  |      |
| Figure (1)  | Gender distribution in all studied patients  | 109  |
| Figure (2)  | Bars chart shows comparison between all studied groups as regard class of epicardial adipose tissue                            | 112  |
| Figure (3)  | Bars chart shows comparison between all studied groups as regard class of coronary artery calcium                              | 113  |
| Figure (4)  | Bars chart shows comparison between all studied groups as regard hemoglobin A1C  | 119  |
| Figure (5)  | Bars chart shows comparison between all studied groups as regard median HOMA-IR  | 119  |
| Figure (6)  | Bars chart shows comparison between all studied groups as regard mean serum TSH  | 121  |



|             |  | Page |
|-------------|--|------|
| Figure (7)  | Bars chart shows comparison between all studied groups as regard mean free T3.                   | 121  |
| Figure (8)  | Bars chart shows comparison between all studied groups as regard median coronary artery calcium  | 123  |
| Figure (9)  | Bars chart shows comparison between all studied groups as regard mean epicardial adipose tissue. | 124  |
| Figure (10) | Correlation between CAC and BMI in all studied groups  | 135  |
| Figure (11) | Correlation between CAC and hemoglobin A1C in all studied groups                                 | 135  |
| Figure (12) | Correlation between CAC and HOMA-IR in all studied groups  | 135  |
| Figure (13) | Correlation between CAC and serum TSH in all studied groups                                      | 135  |
| Figure (14) | Correlation between CAC and UACR in all studied group  | 136  |
| Figure (15) | Correlation between CAC and EAT in all studied groups  | 136  |
| Figure (16) | Correlation between CAC and HOMA-B in all studied groups   | 136  |
| Figure (17) | Correlation between CAC and free T4 in all studied groups  | 136  |
| Figure (18) | Correlation between EAT and BMI in all studied groups  | 140  |
| Figure (19) | Correlation between EAT and hemoglobin A1C in all studied groups                                 | 140  |
| Figure (20) | Correlation between EAT and HOMA-IR in all studied groups  | 140  |
| Figure (21) | Correlation between EAT and serum TSH in all studied groups                                      | 140  |
| Figure (22) | Correlation between EAT and UACR in all studied groups   | 141  |
| Figure (23) | Correlation between EAT and CAC in all studied groups  | 141  |
| Figure (24) | Correlation between EAT and free T3 in all studied groups  | 141  |



## **List of Tables**

|                   |   | Page |
|-------------------|---|------|
| A: Tables         | of the Review:  |      |
| Table (1)         | Sources and functions of key adipokines   | 11   |
| Table (2)         | Main anatomical and clinical characteristics of epicardial fat  | 14   |
| Table (3)         | Known or attributed physiologic and pathophysiological functions of epicardial fat                                  | 16   |
| Table (4)         | Epicardial adipose tissue bioactive molecules   | 20   |
| Table (5)         | Difference of the effects of glycemic control in cardiovascular risk reduction in type 2 diabetes                   | 36   |
| Table (6)         | Stander categories for CAC score  | 83   |
|                   | of the Results:   | 110  |
| Table (1)         | Gender distribution between groups.   | 110  |
| Table (2)         | Comparison between all groups as regard smoking, hypertension and dyslipidemia.                                     | 110  |
| Table (3)         | Comparison between all studied groups as regard antidiabetic treatments   | 111  |
| Table (4)         | Comparison between all groups as regard their family history of DM, HTN and cardiac disease                         | 111  |
| Table (5)         | Comparison between all studied groups as regard class of EAT  | 112  |
| Table (6)         | Comparison between all studied groups as regard class of CAC  | 113  |
| Table (7)         | Comparison between different CAC classes as regard class of epicardial adipose tissue (EAT) class                   | 114  |
| Table (8)         | Comparison between the different studied groups as regard some clinical data using ANOVA                            | 114  |
| Table (9)         | Comparison between the different studied groups as regard lipid profile using ANOVA                                 | 115  |
| <b>Table (10)</b> | Comparison between the different studied groups as regard glucose – insulin profile and serum uric acid using ANOVA | 117  |
| Table (11)        | Comparison between the different studied groups as regard thyroid profile using ANOVA                               | 119  |
| <b>Table (12)</b> | Comparison between the different studied groups as regard coronary artery calcium (CAC)epicardial adipose tissue    | 122  |



|                   |  | Page |
|-------------------|--|------|
| <b>Table (13)</b> | Comparison between the different classes of CAC as regard some clinical data using ANOVA   | 124  |
| <b>Table (14)</b> | Comparison between the different classes of CAC as regard lipid profile using ANOVA  | 125  |
| <b>Table (15)</b> | Comparison between the different classes of CAC as regard glucose-insulin profile, uric acid and UACR using ANOVA                                  | 127  |
| <b>Table (16)</b> | Comparison between the different classes of CAC as regard thyroid profile using ANOVA:   | 129  |
| <b>Table (17)</b> | Comparison between the different classes of CAC as regard EAT using ANOVA:   | 130  |
| <b>Table (18)</b> | Correlation between coronary artery calcium (CAC) and all studied parameters in different groups using Spearman's rank correlation coefficient (rs | 132  |
| <b>Table (19)</b> | Correlation between epicardial adipose tissue (EAT) and all studied parameters in different groups using Pearson's correlation coefficient (r):    | 137  |
| <b>Table (20)</b> | Stepwise regression analysis; Dependent variable: coronary artery calcium  | 142  |
| Table (21)        | Stepwise regression analysis; Dependent variable: Epicardial Adipose Tissue  | 142  |

## **Protocol**



#### Introduction

Visceral adipose tissue (VAT) may be important in sustaining the proinflammatory background of cardiovascular disease. Epicardial, mesenteric and omental fat are the most important VATs and share the same origin from the splanchnopleuric mesoderm (Wang et al., 2012).

Epicardial adipose tissue (EAT) is a special visceral fat depot which surrounds the major branches of the coronary artery and myocardium and is supplied by the coronary artery branches sharing the same myocardial circulation. This close anatomical relationship between EAT and the adjacent coronary artery and myocardium further promotes local paracrine interactions between these tissues (Sacks and Fain, 2007).

Also, EAT is related to impaired fasting plasma glucose levels, insulin resistance and hypertension. In addition, its volume is increased in type 2 diabetes mellitus (T2DM) patients and is associated with unfavorable components of metabolic syndrome and coronary atherosclerosis (Wang et al., 2009).

Cardiovascular disease is the most significant cause of mortality in T2DM and is responsible from 75% of the deaths. The risk of coronary artery disease (CAD) in patients with T2DM is 2 to 4 times higher compared with normal population. The risk of developing MI in patients with DM without history of CAD is identical with persons with CAD without DM (Karabulut et al., 2012).

Microalbuminuria has long been recognized as an important biomarker to predict micro- and macrovascular complications and mortality for patients with T2DM. It is also considered an independent predictor of